Hikma pledges US$1B investment to boost US medicine manufacturing

USA—Hikma Pharmaceuticals USA has announced a major investment plan to boost its manufacturing and research capabilities in the United States.

 The company will invest US$1 billion by 2030 to help meet the growing demand for high-quality medicines made domestically.

This new initiative, called America Leans on Hikma: Quality Medicines Manufactured in the USA, aims to expand Hikma’s already strong presence in the US healthcare system by increasing the production and development of essential medicines for patients across the country.

Hikma has been operating in the US since 1991 and has invested over US$4 billion in the past 15 years to build and enhance its US-based manufacturing and R&D facilities.

Today, Hikma has the capacity to produce over 12 billion finished doses of important medicines annually.

During this time, the company has helped make healthcare more affordable by providing a wide range of generic medicines that cost less than branded drugs.

Hikma also maintains an excellent record with the US Food and Drug Administration (FDA), consistently passing quality inspections and working closely with the FDA to address critical drug shortages.

The announcement was made at a special groundbreaking event at Hikma’s advanced pharmaceutical manufacturing and R&D center in Columbus, Ohio.

 The event was attended by elected officials, including US Representatives Mike Carey (OH-15) and Buddy Carter (GA-01), who praised Hikma’s commitment to American workers and patients.

The America Leans on Hikma initiative will further increase the volume of medicines produced at Hikma’s sites in Columbus and Cleveland, Ohio, as well as Cherry Hill and Dayton, New Jersey.

This expansion will strengthen Hikma’s portfolio, which already includes more than 800 medicines, and boost its capacity to produce large quantities of affordable, high-quality medicines for hospitals, healthcare providers, and patients nationwide.

Dr. Hafrun Fridriksdottir, President of Hikma Rx, expressed pride in continuing the company’s investments in US manufacturing and R&D.

She emphasized Hikma’s dedication to supporting healthier communities by ensuring a reliable supply of domestically produced medicines.

Similarly, Dr. Bill Larkins, President of Hikma Injectables, highlighted that Hikma has become one of the top three US suppliers of sterile injectable medicines by volume, with over 180 injectable products and a growing pipeline.

He noted that the new investment phase will expand their sterile injectables production capabilities, helping them meet patient needs more effectively.

Representative Buddy Carter, a pharmacist and Chairman of the American-Made Medicines Caucus, stressed the importance of onshoring the production of critical generic drugs to keep medicines affordable and accessible.

He pledged to continue working with Hikma to strengthen national security and public health by supporting domestic manufacturing.

Representative Mike Carey also applauded Hikma’s ongoing investment in American workers, particularly in central Ohio, where the new expansion will create jobs and support a vital industry.

She expressed excitement about the additional manufacturing capacity increasing access to affordable medicines and looked forward to visiting the new facility once completed.

Through this significant investment, Hikma reaffirms its mission to provide affordable and accessible healthcare solutions.

 The company’s commitment ensures a steady and reliable supply of essential medications for all Americans, strengthening the nation’s healthcare system and supporting working families.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.